Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Verastem licensed exclusive worldwide rights to develop and commercialise Infinity's oncology product candidate duvelisib...